Drug and Therapeutics Bulletin 1994;32:41-42; doi:10.1136/dtb.1994.32641
Copyright © 1994 by the BMJ Publishing Group Ltd.
Paclitaxel for ovarian cancer
Relevant BNF section: 8.1.5
Paclitaxel (Taxol - Bristol-Myers Squibb) is the first of a new group of cytotoxic drugs, the taxanes. It is licensed for the treatment of patients with metastatic ovarian carcinoma "where standard, platinum-containing, therapy has failed". What is its place in treatment?
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Endocrine system
-
Malignant disease and immunosuppression
-
Endocrinology
-
Oncology
- Paediatrics (drugs and medicines)
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
